上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注当创新药板块近期来到平台震荡阶段,大部分公司短期表现挣扎的背景下,远大医药近两周仍然取得了超过15%的涨幅,今日更是触及9.89港元的高位。市场不会有无缘无故的爱,远大医药2025年创新药板块迎来密集的里程碑催化,备受市场关注的便是全球FIC/BIC脓毒症管线STC3141,其维持免疫稳态的创新机制在临床中获得成药性验证...
Source Link上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,100000+投资菁英共同关注当创新药板块近期来到平台震荡阶段,大部分公司短期表现挣扎的背景下,远大医药近两周仍然取得了超过15%的涨幅,今日更是触及9.89港元的高位。市场不会有无缘无故的爱,远大医药2025年创新药板块迎来密集的里程碑催化,备受市场关注的便是全球FIC/BIC脓毒症管线STC3141,其维持免疫稳态的创新机制在临床中获得成药性验证...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.